Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.9
5.2
Journals
Vaccines
Special Issues
Exploring the Gut Microbiota, Immunonutrition Axis in Vaccine Therapy: Probiotics...
share announcement

Exploring the Gut Microbiota, Immunonutrition Axis in Vaccine Therapy: Probiotics for Healthy Living

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 5258

Special Issue Editors

Dr. Irfan A. Rather

E-Mail Website
Guest Editor
1. Department of Biological Sciences, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia
2. Department of Applied Microbiology and Biotechnology, Yeungnam University, Gyeongsan-si, Gyeongbuk-so, Korea
3. Probionic Corporation, Jeonbuk Institute for Food-Bioindustry, Jeonju 54810, Korea
Interests: zoonotic diseases; gut microbiome, immunonutrition, probiotics, respiratory infections
Special Issues, Collections and Topics in MDPI journals
Dr. Yan-Yan Hor

E-Mail Website
Guest Editor
Centre for Bioinformatics, School of Data Sciences, Perdana University, Suite 9.2, 9th Floor, Wisma Chase Perdana, Changkat Semantan, Wilayah Persekutuan, Kuala Lumpur 50490, Malaysia
Interests: structural bioinformatics; molecular dynamics simulation; membrane protein simulation; molecular docking; protein structure pred
Special Issues, Collections and Topics in MDPI journals
Dr. Sy-Bing Choi

E-Mail Website
Guest Editor
Centre for Bioinformatics, School of Data Sciences, Perdana University, Suite 9.2, 9th Floor, Wisma Chase Perdana, Changkat Semantan, Wilayah Persekutuan, Kuala Lumpur 50490, Malaysia
Interests: structural bioinformatics; molecular dynamics simulation; membrane protein simulation; molecular docking; protein structure pred
Dr. Majid Rasool Kamli

E-Mail Website
Guest Editor
Department of Biological Sciences, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia
Interests: bacterial genetics; environmental genomics; viral genomics; bioactive nanomaterials

Special Issue Information

Dear Colleagues,

The human microbiota and the immune system co-evolve due to ongoing crosstalk between the two systems. A close association within the gut microbiome and its diversity may play a role in modulating host immunity. In addition, it actively interacts with therapeutic drugs, which makes the gut microbiome an intriguing target for modifying drug efficacy, including vaccines. Vaccines are effective health measures in eradicating numerous diseases; however, the response rates are low in some individuals. Reports suggest that differences in the state of the host immune system may be critical to their ability to respond to vaccines. One of the apparent and effective mechanisms of modulating the gut microbiome is via nutrition. An immunonutritional approach focuses on the application of nutrients in therapy.

This Special Issue will focus on the importance of nutrition and microbiota modulation in promoting a healthy immune system while also discussing the overall impact on the vaccination response. It will also focus on the potential of utilizing novel, innovative technologies to allow a more profound investigation across the human microbiome–immune axis in vaccine therapy.

Moreover, this Special Issue will also focus on probiotics, prebiotics, nutraceuticals, and antioxidants to alleviate the gut microbiome, which could be related to the synthesis of metabolites not limited to short-chain fatty acids or vitamins, thereby ameliorating chronic infections, inflammatory disorders, or respiratory infections not limited to sinus, whooping cough, and chest congestion.

We encourage authors to submit research articles, reviews, case studies, and clinical trials.

Dr. Irfan A. Rather
Dr. Yan-Yan Hor
Dr. Sy-Bing Choi
Dr. Majid Rasool Kamli
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gut microbiota
  • metabolites
  • immunonutrition
  • vaccines
  • inflammation
  • probiotics
  • sinus, nasal congestion
  • cold

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

10 pages, 1618 KiB  
Article
A Subtraction Genomics-Based Approach to Identify and Characterize New Drug Targets in Bordetella pertussis: Whooping Cough
by Alam Jamal, Sadaf Jahan, Hani Choudhry, Irfan A. Rather and Mohammad Imran Khan
Vaccines 2022, 10(11), 1915; https://doi.org/10.3390/vaccines10111915 - 12 Nov 2022
Cited by 4 | Viewed by 1816
Abstract
Bordetella pertussis is a Gram-negative bacterium known to cause pertussis or whooping cough. The disease affects the respiratory system and is contagious. Pertussis causes high mortality among infants aged less than one-year-old, although it can affect anyone of any age. Globally, 16 million [...] Read more.
Bordetella pertussis is a Gram-negative bacterium known to cause pertussis or whooping cough. The disease affects the respiratory system and is contagious. Pertussis causes high mortality among infants aged less than one-year-old, although it can affect anyone of any age. Globally, 16 million cases of pertussis were reported in 2008, 95% of which were in developing nations, and approximately 195,000 children died from the disease. Under a computational subtractive genomics approach, the total proteome of a pathogen is gently trimmed down to a few potential drug targets. First, from NCBI, we obtained the pathogen proteins followed by CD hit for removal of duplicate proteins. The BLAST step was applied to find non-similar proteins, and then, we applied BLAST to these non-similar bacterial proteins with DEG to find essential bacterial proteins. After this, to find the location, these vital proteins were screened via PSORTb; the majority of proteins were in cytoplasm. The KASS server was used to determine the involvement of these proteins in the metabolic pathways of bacteria, and KEGG was applied to find the unique metabolic pathways of the pathogen. Finally, we applied BLAST to these vital, unique, and non-similar proteins with FDA-approved drug targets, and four proteins of the B. pertussis strain B1917 were identified that might be powerful drug targets. A variety of therapeutic molecules could be designed to target these proteins in order to treat infections caused by bacteria. Full article
(This article belongs to the Special Issue Exploring the Gut Microbiota, Immunonutrition Axis in Vaccine Therapy: Probiotics for Healthy Living)
►▼ Show Figures

Figure 1

Review

Jump to: Research

30 pages, 1933 KiB  
Review
The Debate between the Human Microbiota and Immune System in Treating Aerodigestive and Digestive Tract Cancers: A Review
by Cátia Domingues, Cristiana Cabral, Ivana Jarak, Francisco Veiga, Marília Dourado and Ana Figueiras
Vaccines 2023, 11(3), 492; https://doi.org/10.3390/vaccines11030492 - 21 Feb 2023
Cited by 1 | Viewed by 2956
Abstract
The human microbiota comprises a group of microorganisms co-existing in the human body. Unbalanced microbiota homeostasis may impact metabolic and immune system regulation, shrinking the edge between health and disease. Recently, the microbiota has been considered a prominent extrinsic/intrinsic element of cancer development [...] Read more.
The human microbiota comprises a group of microorganisms co-existing in the human body. Unbalanced microbiota homeostasis may impact metabolic and immune system regulation, shrinking the edge between health and disease. Recently, the microbiota has been considered a prominent extrinsic/intrinsic element of cancer development and a promising milestone in the modulation of conventional cancer treatments. Particularly, the oral cavity represents a yin-and-yang target site for microorganisms that can promote human health or contribute to oral cancer development, such as Fusobacterium nucleatum. Moreover, Helicobacter pylori has also been implicated in esophageal and stomach cancers, and decreased butyrate-producing bacteria, such as Lachnospiraceae spp. and Ruminococcaceae, have demonstrated a protective role in the development of colorectal cancer. Interestingly, prebiotics, e.g., polyphenols, probiotics (Faecalibacterium, Bifidobacterium, Lactobacillus, and Burkholderia), postbiotics (inosine, butyrate, and propionate), and innovative nanomedicines can modulate antitumor immunity, circumventing resistance to conventional treatments and could complement existing therapies. Therefore, this manuscript delivers a holistic perspective on the interaction between human microbiota and cancer development and treatment, particularly in aerodigestive and digestive cancers, focusing on applying prebiotics, probiotics, and nanomedicines to overcome some challenges in treating cancer. Full article
(This article belongs to the Special Issue Exploring the Gut Microbiota, Immunonutrition Axis in Vaccine Therapy: Probiotics for Healthy Living)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop